


# TRANSFORMATIVE THERAPIES | TARGETING CANCER

Seattle Genetics, Inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives.

ADCETRIS® (brentuximab vedotin) uses the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, we have established a pipeline of novel targeted therapies at various stages of clinical testing. Positive data from the enfortumab vedotin pivotal trial were presented at the American Society of Clinical Oncology in June 2019 and serve as the basis for a Biologics License Application to the FDA under its accelerated approval pathway. Both enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin in clinical trials for metastatic cervical cancer use our proprietary ADC technology. In addition, tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. We are leveraging our expertise in empowered antibodies and targeted therapies to build a portfolio of programs for hematologic malignancies and solid tumors.

Our ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.



Various combinations of these novel modalities are likely to be the future of treatment in oncology

## QUICK FACTS

- YEARS:** In oncology for 20+ years
- SIZE:** Largest biotechnology company with headquarters in the Pacific Northwest
- EMPLOYEES:** 1,500+ employees worldwide
- PASSION:** Helping people with cancer
- LEADERS IN:** Antibody-drug conjugate (ADC) technology
- COMMERCIAL PRODUCT:** ADCETRIS® (brentuximab vedotin) for multiple CD30-expressing lymphomas
- RESEARCH & DEVELOPMENT:** >750 scientists dedicated to developing our next innovations, and medical and clinical researchers focused on improving patient outcomes with targeted treatment options, including multiple unique programs in ongoing pivotal clinical trials
- COLLABORATIONS:** Multiple ADC technology licensing agreements; co-development collaborations with other oncology industry leaders
- LOCATIONS:** Greater Seattle and South San Francisco, United States; Zug, Switzerland

For more information on our company and our robust pipeline, we encourage you to visit [www.seattlegenetics.com](http://www.seattlegenetics.com) and follow @SeattleGenetics on Twitter.

These are investigational uses/agents and efficacy/safety have not been established. There is no guarantee that these agents will receive regulatory approval and become commercially available for uses being investigated.

## ADVANCING LATE-STAGE CLINICAL TRIALS AND AN EXPANDING DEVELOPMENT PORTFOLIO

PROGRAM / TUMOR TYPE	PHASE 1	PHASE 2	PHASE 3	PARTNER
----------------------	---------	---------	---------	---------

### Brentuximab vedotin

ADCETRIS® (brentuximab vedotin) is currently approved in the U.S. for six indications for certain CD30-expressing lymphomas. We continue to evaluate ADCETRIS in a broad clinical development program.

Frontline Hodgkin lymphoma (HL)	Stage 3/4 HL (ADCETRIS, nivolumab and AD)			
Relapsed HL and PTCL	Retreatment with ADCETRIS			
Frontline HL or PTCL (unfit for combo chemotherapy)	Single-agent ADCETRIS			
Relapsed HL (pediatrics)	CheckMate 744: combination with nivolumab			
Second-line HL	Combination with nivolumab			

### Enfortumab Vedotin

Metastatic urothelial cancer	EV-301: post PD-1 or PD-L1 inhibitor		BLA filed by U.S. FDA; PDUFA March 2020	
	EV-201: post PD-1 or PD-L1 inhibitor			
First-line metastatic and muscle invasive urothelial cancer	EV-103: combination w/ platinum agents and/or pembrolizumab			

### Tucatinib

Metastatic HER2+ breast cancer	HER2CLIMB: combination with chemotherapy	NDA Submission to U.S. FDA Planned 1Q 2020	
	HER2CLIMB-02: combination with T-DM1		
Metastatic HER2+ colorectal cancer	MOUNTAINEER: combination with trastuzumab		
Neoadjuvant breast cancer	I-SPY 2		

### Tisotumab Vedotin

Recurrent/metastatic cervical cancer	innovaTV 204	Pivotal	
First-line cervical cancer	innovaTV 205		
Other solid tumors	innovaTV 207		
Ovarian cancer	innovaTV 208		

For a more comprehensive list of trials including, several earlier-stage proprietary targeted therapies, visit our website for details. [www.seattlegenetics.com](http://www.seattlegenetics.com)

These are investigational uses/agents and efficacy/safety have not been established.

There is no guarantee that these agents will receive regulatory approval and become commercially available for uses being investigated.